{
    "clinical_study": {
        "@rank": "41865", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Experimental", 
                "description": "Days 1-7 = IDX719 150 mg once daily + ritonavir 30 mg once daily\nDays 8-14 = IDX719 150 mg once daily + simeprevir 75 mg once daily + TMC647055 450 mg once daily + ritonavir 30 mg once daily"
            }, 
            {
                "arm_group_label": "group B", 
                "arm_group_type": "Experimental", 
                "description": "Days 1-7 = simeprevir 75 mg once daily + TMC647055 450 mg once daily + ritonavir 30 mg once daily\nDays 8-14 = IDX719 150 mg once daily + simeprevir 75 mg once daily + TMC647055 450 mg once daily + ritonavir 30 mg once daily"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the potential for a PK drug-drug interaction when\n      IDX719, simeprevir, TMC647055 and low-dose ritonavir (RTV) are administered in combination.\n      Safety and tolerability will also be assessed."
        }, 
        "brief_title": "Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and a Pharmacokinetic Enhancer When Administered in Combination in Healthy Subjects", 
        "condition": "Hepatitis C, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Read and signed the written informed consent form (ICF) after the nature of the study\n             has been fully explained.\n\n          -  All subjects of childbearing potential must have agreed to use a double method of\n             birth control (one of which must be a barrier) from Screening through at least 90\n             days after the last dose of the study drug.\n\n          -  Male subjects have agreed not to donate sperm from Day -1 through 90 days after the\n             last dose of study drug.\n\n        Exclusion Criteria:\n\n          -  Pregnant or breastfeeding.\n\n          -  Other clinically significant medical conditions or laboratory abnormalities."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01907724", 
            "org_study_id": "IDX-06A-007"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group A", 
                    "group B"
                ], 
                "description": "IDX719 will be supplied as a 50 mg tablet", 
                "intervention_name": "IDX719", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group A", 
                    "group B"
                ], 
                "description": "Simeprevir will be supplied as 75 mg capsules", 
                "intervention_name": "Simeprevir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group A", 
                    "group B"
                ], 
                "description": "TMC647055 will be supplied as 150 mg capsules", 
                "intervention_name": "TMC647055", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group A", 
                    "group B"
                ], 
                "description": "RTV will be supplied as 80 mg/mL oral solution", 
                "intervention_name": "RTV", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Chronic hepatitis C", 
            "Hepatitis C virus", 
            "HCV"
        ], 
        "lastchanged_date": "August 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lincoln", 
                    "country": "United States", 
                    "state": "Nebraska", 
                    "zip": "68502"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Randomized, Multiple-Dose Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and a Pharmacokinetic Enhancer When Administered in Combination in Healthy Subjects", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Pharmacokinetic measures of plasma drug exposure (AUCss, Ctrough and Cmax) of IDX719, simeprevir, TMC647055 and low-dose RTV.", 
            "measure": "Evaluation of PK drug-drug interaction", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01907724"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Proportions of subjects experiencing adverse events.", 
            "measure": "Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "14 Days"
        }, 
        "source": "Idenix Pharmaceuticals", 
        "sponsors": {
            "collaborator": {
                "agency": "Janssen Research & Development, LLC", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Idenix Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}